Fenamic acid

Research use only, not for human use.

Fenamic acid is a chloride channel blocker that causes renal papillary necrosis in rats. Fenamic acid serves as a parent structure for several nonsteroidal anti-inflammatory drugs (NSAIDs), including flufenamic acid, tolfenamic acid, mefenamic acid, and meclofenamic acid.

Fenamic acid is a chloride channel blocker that causes renal papillary necrosis in rats. Fenamic acid serves as a parent structure for several nonsteroidal anti-inflammatory drugs (NSAIDs), including flufenamic acid, tolfenamic acid, mefenamic acid, and meclofenamic acid.

Fenamic acid (N-Phenylanthranilic acid, NPAA) (2.5 mM; 3 h) inhibits Cl- transportation and blocks 36C1- uptake and efflux in endothelial cells.Fenamic acid exhibits selectivity to AKR1B10 (the tumor-marker) over human AR, and inhibits AKR1B10 with IC50s of 0.76 μM (Flufenamic acid), 1.6 μM (Mefenamic acid), 9.89 μM (Meclofenamic acid), respectively.Fenamic acid (4-16 μg/mL; 72 h) inhibits 50% of Neisseria gonorrhoeae with an MIC50 value from 4 to 16 μg/mL (tolfenamic acid, flufenamic acid, and meclofenamic acid) in a low frequency of resistance. Fenamic acid (2-8 μg/mL; 8 h) reduces the expression of the porinflammatory cytokines (IL-8, IL-6 and IL-?) by infected endocervical cells without (>128 μg/mL; 24 h) inhibition towards commensal Lactobacillus spp. belonging healthy female genital microbiota.

RPA-1 is a biomarker in the detection of collecting duct injury in papillary necrosis in male rats.Fenamic acid (N-Phenylanthranilic acid, NPAA) (350-700 mg/kg/day; o.p.; 4 d, 8 d, and 15 d) causes renal papillary necrosis and increases urinary renal papillary antigen-1 (RPA-1) in rats.Fenamic acid (20 g/0.2 mL; i.p.) shows inhibitory effect against the abdominal constriction induced by acetic acid in mice. Animal Model:Male Wistar Hannover rats (8-10 weeks old; weighting 220-270 g)Dosage:50, 350, or up to 700 mg/kg Administration:Oral gavage; once daily; 7 days or 14 days Result:Increased absolute paired kidney weights (13.8% at 350 mg/kg and 21.2% at 700/500 mg/kg) and relative to body weight (10.5% at 350 mg/kg/day and 20.3% at 700/500 mg/kg/day).Caused minimal papillary necrosis of tip with necrosis, hemorrhage, and inflammation of collecting ducts.Animal Model:Male NMRI mice (weighting 20-25 g); abdominal constriction model (writhing test), induced by acetic acid Dosage:100 g/mL, each mice injected with 20 mL Administration:Intraperitoneal injection; once Result:Showed anti-nociceptive activity and inhibited the abdominal constriction with the maximal inhibition of 96.3% (Mefenamic acid).

N-Phenylanthranilic acid | 2-(Phenylamino)benzoic acid | 2-Anilinobenzoic acid | Diphenylamine-2-carboxylic acid

Membrane Transporter/Ion Channel

Chloride Channel

Apoptosis

——

——

91-40-7

213.236

C13H11NO2

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (586.22 mM)

OC(=O)c1ccccc1Nc1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years